Enhanced Hydrophobic Auristatin F Conjugates for Improved Cancer Treatment

This inventive concept relates to hydrophobic Auristatin F (AF) compound conjugates with modified linker moieties, targeting moieties, and C-terminal carboxylic acid functional groups that exhibit enhanced bystander activity against nearby cancer cells with lower copy number or undetectable levels of the targeted antigen, while maintaining cytotoxic activity towards targeted cancer cells with higher copy number of the targeted antigen.

Traditional antibody-auristatin drug conjugates either exhibit activity against MDR+ cancer cells or have bystander activity, but no single agent has been able to achieve both. The original patent disclosed hydrophobic AF compounds and conjugates, but these compounds still had limitations in terms of bystander activity and treatment outcomes. This inventive concept addresses these limitations by introducing modified linker moieties, targeting moieties, and C-terminal carboxylic acid functional groups that enhance bystander activity and improve treatment outcomes in MDR+ cancer cells.

The inventive concept comprises hydrophobic AF compound conjugates with modified linker moieties that increase the hydrophobicity of the AF compound, thereby enhancing bystander activity against nearby cancer cells with lower copy number or undetectable levels of the targeted antigen. The conjugates may also include targeting moieties that specifically bind to cancer cells with higher copy number of the targeted antigen, and C-terminal carboxylic acid functional groups modified with hydrophobic moieties to enhance permeability into cancer cells. The modified linker moieties and targeting moieties work synergistically to improve treatment outcomes in MDR+ cancer cells.

The inventive concept is novel and non-obvious in that it introduces modified linker moieties, targeting moieties, and C-terminal carboxylic acid functional groups that enhance bystander activity and improve treatment outcomes in MDR+ cancer cells. The combination of these modifications provides a synergistic effect that is not apparent from the original patent or prior art.

Alternative embodiments of the inventive concept may include varying the structure of the modified linker moieties, targeting moieties, and C-terminal carboxylic acid functional groups to optimize bystander activity and treatment outcomes. Additionally, the inventive concept may be adapted for use with different types of cancer cells and targeted antigens.

The inventive concept has significant commercial potential in the field of cancer treatment, particularly for MDR+ cancer cells. The enhanced bystander activity and improved treatment outcomes provided by the modified linker moieties, targeting moieties, and C-terminal carboxylic acid functional groups make this inventive concept an attractive solution for pharmaceutical companies and researchers seeking to develop more effective cancer therapies.